Lung Cancer Clinical Trials in Austin

Showing 141-160 of 268 trials

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

NCT05094804

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.

CancerTumor, SolidMalignant Neoplasm+7 more

OncoResponse, Inc.172 participantsStarted Sep 2021

Scottsdale, Arizona, United States • Austin, Texas, United States • San Antonio, Texas, United States

TERMINATEDPHASE174 miles

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric Cancer+9 more

ADC Therapeutics S.A.78 participantsStarted Nov 2018

Palo Alto, California, United States • New Haven, Connecticut, United States • Portland, Oregon, United States +6 more locations

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Lung Cancer Trials in Other Cities

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Lung EpiCheck Biomarkers Development Study

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Other Conditions in Austin